Patents by Inventor Matthew Davison

Matthew Davison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treating inflammation using antibodies to kallidin and des-Arg-kallidin
    Patent number: 12558420
    Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.
    Type: Grant
    Filed: December 9, 2022
    Date of Patent: February 24, 2026
    Assignee: SANOFI
    Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
  • ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES
    Publication number: 20250313651
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Application
    Filed: December 12, 2024
    Publication date: October 9, 2025
    Inventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON
  • METHODS FOR TREATING INFLAMMATION USING ANTIBODIES TO KALLIDIN AND DES-ARG10-KALLIDIN
    Publication number: 20230399388
    Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.
    Type: Application
    Filed: December 9, 2022
    Publication date: December 14, 2023
    Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
  • ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES
    Publication number: 20230235088
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Application
    Filed: August 10, 2022
    Publication date: July 27, 2023
    Inventors: Ercole RAO, Vincent Mikol, Danxi Li, Jochen Kruip, Matthew Davison
  • Antibodies that bind IL-4 and/or IL-13 and their uses
    Patent number: 11453727
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: September 27, 2022
    Assignee: SANOFI
    Inventors: Ercole Rao, Vincent Mikol, Danxi Li, Jochen Kruip, Matthew Davison
  • ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES
    Publication number: 20210047437
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Application
    Filed: July 28, 2020
    Publication date: February 18, 2021
    Inventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON
  • Antibodies that bind IL-4 and/or IL-13 and their uses
    Patent number: 10759871
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: September 1, 2020
    Assignee: SANOFI
    Inventors: Ercole Rao, Vincent Mikol, Danxi Li, Jochen Kruip, Matthew Davison
  • METHODS FOR TREATING INFLAMMATION USING ANTIBODIES TO KALLIDIN AND DES-ARG10-KALLIDIN
    Publication number: 20200115441
    Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.
    Type: Application
    Filed: September 24, 2019
    Publication date: April 16, 2020
    Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
  • Nucleic acids encoding antibodies to Kallidin and des-Arg-Kallidin and host cells comprising the same
    Patent number: 10465002
    Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: November 5, 2019
    Assignee: SANOFI
    Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
  • METHODS FOR TREATING PAIN USING ANTIBODIES TO KALLIDIN AND DES-ARG10-KALLIDIN
    Publication number: 20180222967
    Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.
    Type: Application
    Filed: December 18, 2017
    Publication date: August 9, 2018
    Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
  • ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES
    Publication number: 20180030156
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Application
    Filed: July 10, 2017
    Publication date: February 1, 2018
    Inventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON
  • Methods for treating pain using antibodies to Kallidin and des-Arg-Kallidin
    Patent number: 9879079
    Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: January 30, 2018
    Assignee: SANOFI
    Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
  • Antibodies that bind IL-4 and/or IL-13 and their uses
    Patent number: 9738728
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: August 22, 2017
    Assignee: Sanofi
    Inventors: Ercole Rao, Vincent Mikol, Danxi Li, Jochen Kruip, Matthew Davison
  • Antibodies that bind IL-4 and/or IL-13 and their uses
    Patent number: 9732162
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 15, 2017
    Assignee: Sanofi
    Inventors: Ercole Rao, Vincent Mikol, Danxi Li, Jochen Kruip, Matthew Davison
  • ANTIBODIES TO KALLIDIN AND DES-ARG9-KALLIDIN
    Publication number: 20160368976
    Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kanidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kanidin activity or detect Kallidin or des-Arg10-Kanidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.
    Type: Application
    Filed: May 25, 2016
    Publication date: December 22, 2016
    Applicant: Sanofi
    Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
  • Antibodies to kallidin and des-Arg-kallidin
    Patent number: 9376494
    Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: June 28, 2016
    Assignee: Sanofi
    Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
  • CONSOLE SERVER WITH USB CONSOLE PORT
    Publication number: 20160170931
    Abstract: A console server that can be configured to include USB and RJ-45 serial ports is disclosed. The USB serial ports are provided by a USB serial card, and are configured to provide communications with a device having a USB serial port, but lacking an RJ-45 serial port.
    Type: Application
    Filed: December 11, 2015
    Publication date: June 16, 2016
    Inventors: Van Quach, Matthew Davison
  • ANTIBODIES TO BRADYKININ B1 RECEPTOR LIGANDS
    Publication number: 20150050270
    Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 19, 2015
    Applicant: SANOFI
    Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritzker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
  • ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES
    Publication number: 20140023649
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Application
    Filed: March 15, 2013
    Publication date: January 23, 2014
    Applicant: SANOFI
    Inventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON
  • ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES
    Publication number: 20130259866
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Application
    Filed: March 11, 2013
    Publication date: October 3, 2013
    Applicant: SANOFI
    Inventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON